Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Abstract Objective: To assess the efficacy of cannabis for the treatment of acute migraine. Background: Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine. Methods: In this randomized, double‐blind, placebo‐controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9‐tetrahydrocannabinol (THC) (THC‐dominant), (2) 11% cannabidiol (CBD) (CBD‐dominant), (3) 6% THC + 11%